XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.06

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: opalapril who wrote (3877)	9/23/1997 9:20:00 AM
From: aknahow	of 17367

Agree it's important news but thought this was only the inital safety study, as well as absorption, distribution in body etc. Did not see this as even phase I. Xoma uses the terms clinical study, clinical program, pilot study. Am I wrong on this? Do these things represent phase 1? Just as Dr. Gioir led Xoma to investigate BPI as a treatment for meningococcemia so did the FDA suggest they, (XOMA), work with CF patients as a means of enhancing the probabilities of findining a pool of people resistant to drugs. I think you are correct that the is more here but Xoma has been up front telling everyone that the FDA is interested in this area and has made helpful suggestions. This has implications as they move foreward. The FDA obviously won't give them any break or slack but I think they will continue to provide their best thinking in ways that may be helpful.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next